Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Bristol-Myers Squibb (NY: BMY )

49.27 +0.12 (+0.25%)
Streaming Delayed Price Updated: 10:44 AM EDT, Apr 23, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Bristol-Myers Squibb

< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Novartis Stock Gains On European Drugmaker's Q1 Earnings Surprise, Lifts Annual Outlook
Discover Novartis' Q1 EPS soars 17% to $1.80, surpassing estimates. Sales hit $11.83B, up 10%. Entresto sales surge 36%, Cosentyx up 25%. CEO Vas Narasimhan bullish on mid & long-term growth. 
Via Benzinga
5 Crash-Proof Stocks to Buy Immediately
We may not be headed to a full-blown crisis, but savvy investors should protect their portfolios now with these crash-proof stocks. 
Via InvestorPlace
Bristol Myers Squibb and Cellares Announce a $380M Worldwide Capacity Reservation and Supply Agreement for the Manufacture of CAR T Cell Therapies to Bring the Promise of Cell Therapy to More Patients, Faster
From Bristol Myers Squibb
Via Business Wire
A Closer Look at Bristol-Myers Squibb's Options Market Dynamics
Via Benzinga
Market Whales and Their Recent Bets on BMY Options
Via Benzinga
Peering Into Bristol-Myers Squibb's Recent Short Interest
Via Benzinga
Can Magnificent 7 Help Script Market Turnaround? Earnings Pick Up Pace With Microsoft, Meta, Alphabet And Tesla Expected This Week
Corporate profit growth rose in Q3 2023 and is expected to continue in Q1. 
Via Benzinga
3 High-Yielding Dividend Stocks That Are Trading at Dirt-Cheap Valuations
These stocks pay between 3.2% and 6.7% in dividends. 
Via The Motley Fool
These 3 Small-Cap Stocks Are Up 304% in 2024. Can They Run Higher?
Small-cap stocks have been the market laggards but these standouts showed how to beat even top-tier tech names at their own game. 
Via InvestorPlace
FDA Mandates "Boxed Warning" For Bristol Myers, Johnson & Johnson CAR-T-Based Blood Cancer Therapies
Following an investigation announced in November last year, the FDA said on Thursday that it would now require boxed warnings—the highest safety-rel 
Via Benzinga
Exposures Product Safety
Got $500? 3 Healthcare Stocks to Buy and Hold Forever
Make the most of a modest investment by putting it into Intuitive Surgical, Bristol Myers Squibb, and Novo Nordisk. 
Via The Motley Fool
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
Via AB Newswire
Topics Economy
Exposures Interest Rates
This Is What Whales Are Betting On Bristol-Myers Squibb
Via Benzinga
3 Undervalued Dividend Stocks to Buy Now to Beat the S&P 500
If you want to outperform the S&P 500, consider these undervalued dividend stocks for juicy yields and high total return potential. 
Via InvestorPlace
Topics Stocks
Exposures US Equities
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
These income stocks look like good options at current levels. 
Via The Motley Fool
3 Pharma Stocks That Are Money-Printing Machines in 2024
The economy, and pharma industry, are projected to grow massively. You should invest in these top three pharma stocks. 
Via InvestorPlace
Topics Economy
Exposures Economy
Neumora Stock Hits 2024 Low As Side Effects In Rabbits Torpedo Schizophrenia Drug
The company was testing a potential treatment for schizophrenia in rabbits, but found a notable side effect. 
Via Investor's Business Daily
Better Buy: Bristol Myers Squibb or the Vanguard S&P 500 ETF?
Bristol Myers Squibb stock sports an attractive valuation and dividend yield. Is it a more compelling buy than the Vanguard S&P 500 ETF? 
Via The Motley Fool
Topics Stocks
Exposures US Equities
Better Growth Play: Merck or The Vanguard Growth Index Fund?
Merck's shares are trading in bargain territory. Are they a better growth play than this popular Vanguard fund? 
Via The Motley Fool
Small-Cap Cancer Drug Developer Agenus' Highlights Encouraging Data From Colorectal Cancer, But Funding Concerns Loom
The latest Phase 1 trial results of Agenus' botensilimab and balstilimab (BOT/BAL) combination therapy for metastatic CRC showcase promising clinical activity. 
Via Benzinga
Wall Street Favorites: 3 Warren Buffett Stocks With Strong Buy Ratings for April 2024
If you’re wondering where to invest in a stock picker's market, these three Warren Buffett stocks are a good place to start. 
Via InvestorPlace
If You Can Only Buy One Biotech Stock in April, It Better Be One of These 3 Names
Capitalize on the biotech sector's boom with these three top biotech stocks to buy, driven by aging demographics and advanced treatments. 
Via InvestorPlace
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease. 
Via InvestorPlace
The Pharmaceutical Industry Finds Itself At A Historical Crossroads
Bristol Myers Squibb (NYSE: BMY), Merck & Co Inc (NYSE: MRK), Pfizer Inc (NYSE: PFE) and Johnson & Johnson(NYSE: 
Via Benzinga
2 High-Yield Dividend Stocks Billionaires Are Buying Hand Over Fist
These reliable dividend payers offer yields of 3.3% and better at recent prices. 
Via The Motley Fool
3 Dividend Growth Stocks With Yields Above 3% That You Can Buy and Hold for the Next Decade
Income-seeking investors can look forward to steady payout raises from these pharma stocks. 
Via The Motley Fool
Bristol Myers Squibb's Acquired Adagrasib Combo Therapy May Benefit Colorectal Cancer Patients With Certain Mutation
Bristol Myers Squibb's latest data on Krazati (adagrasib) in combination with cetuximab for KRASG12C-mutated colorectal cancer. Promising objective response rates and progression-free survival. FDA... 
Via Benzinga
Exposures Product Safety
KRAZATI (adagrasib) in Combination with Cetuximab Demonstrates Clinically Meaningful Activity as a Targeted Treatment Option for Patients with Previously Treated KRAS G12C-Mutated Locally Advanced or Metastatic Colorectal Cancer (CRC)
From Bristol Myers Squibb
Via Business Wire
Bristol Myers' $14B Bet On Schizophrenia - Drug Cuts Symptoms Without Common Side Effect Of Weight Gain Associated With Other Antipsychotics
Interim data from Bristol Myers Squibb's Phase 3 EMERGENT program on KarXT's safety, tolerability, and metabolic outcomes in adults with schizophrenia. Find out how KarXT demonstrated favorable impacts... 
Via Benzinga
Down 75%. Is Agenus Stock a Buy on the Dip?
Wall Street analysts who watch the cancer drug developer closely think it could rocket higher. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
54 55 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.